50,231 Pfizer Inc. $PFE Shares Bought by Vise Technologies Inc.

Key Points

• Vise Technologies increased its Pfizer stake by 16% in the third quarter, buying 50,231 additional shares for a total of 364,384 shares valued at approximately $10.4 million.
• Institutional ownership remains substantial at 68.36%, with major investors including BlackRock and State Street increasing their positions.
• Analysts maintain a consensus “Hold” rating with an average price target of $28.65, while Pfizer’s 5.6% dividend yield is attractive but its 226% payout ratio raises concerns about long-term coverage.

Vise Technologies Inc. raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 16.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 364,384 shares of the biopharmaceutical company's stock after buying an additional 50,231 shares during the quarter. Vise Technologies Inc.'s holdings in Pfizer were worth $10,392,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Bank of America Corp DE bought a new stake in shares of Pfizer during the second quarter valued at approximately $1,049,602,000. BlackRock Inc. lifted its holdings in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares in the last quarter. Nykredit A S bought a new position in shares of Pfizer in the 2nd quarter worth $205,774,000. Assenagon Asset Management S.A. grew its position in Pfizer by 96.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company's stock valued at $286,609,000 after purchasing an additional 5,829,204 shares during the period. Finally, State Street Corp grew its position in Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Scotiabank upped their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an "outperform" rating in a report on Tuesday, October 6th. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a report on Saturday, October 10th. Weiss Ratings upgraded shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. BMO Capital Markets dropped their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, July 13th. Finally, HSBC lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday, September 10th. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $28.65.

Pfizer Trading Down 0.1%

Shares of Pfizer stock opened at $30.48 on Monday. Pfizer Inc. has a 1 year low of $23.62 and a 1 year high of $30.67. The company has a 50 day simple moving average of $28.55 and a two-hundred day simple moving average of $26.79. The firm has a market cap of $173.73 billion, a PE ratio of 40.11, a PEG ratio of 2.07 and a beta of 0.31. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm's revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer's dividend payout ratio is 226.32%.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.